Little Spark Yet For Xelpros Amid New CRL

 
• By Anju Ghangurde

Sun Pharma Advanced Research Company (SPARC) has received a second complete response letter (CRL) from the FDA to its new drug application (NDA) for Xelpros (latanoprost BAK-free eyedrops), though the company claims this concerns "minor" labelling modifications.

More from India

More from Focus On Asia